肿瘤治疗电场(TTFields)对人间充质基质细胞的影响
研究在胶质母细胞瘤患者样本中确认了肿瘤相关间充质基质细胞(MSC)的存在,并在体外评估肿瘤治疗电场(TTFields)对人骨髓来源MSC的影响。结果显示TTFields使MSC增殖和克隆存活分别降低最多60%和90%,并增加凋亡和衰老、降低迁移能力,而表面标志物表达和多向分化能力保持完好。
要点
- 胶质母细胞瘤患者样本中可见肿瘤相关间充质基质细胞。
- TTFields使体外培养的人骨髓MSC增殖和克隆存活分别降低最多60%和90%。
- TTFields增加MSC凋亡和衰老并降低迁移能力,但表面标志物与分化能力完好。
核心结论
- 研究证明胶质母细胞瘤患者中存在肿瘤相关MSC,为研究TTFields对MSC的影响提供依据。
- TTFields显著增加MSC的凋亡和衰老,导致其存活和迁移受损。
- 结果为后续分析接受TTFields治疗的胶质母细胞瘤患者中MSC的作用提供基础。
研究设计与样本
- 采用单细胞RNA测序和免疫荧光染色在患者样本中识别胶质母细胞瘤相关MSC。
- 体外评估人骨髓来源MSC在TTFields后的增殖和克隆存活。
- 用流式细胞术检测MSC特征性表面标志物表达,用免疫组化检测多向分化潜能。
- 基于caspase-3和annexin-V/7-AAD水平用流式细胞术定量凋亡,用β-半乳糖苷酶染色评估衰老。
- 用Boyden小室实验评估MSC迁移能力。
主要发现
- 单细胞RNA测序和免疫荧光显示患者样本中存在胶质母细胞瘤相关MSC。
- TTFields使人工培养的人骨髓来源MSC增殖降低最多60%,克隆存活降低最多90%。
- TTFields后MSC特征性表面标志物表达和多向分化能力保持完好。
- TTFields导致MSC凋亡和衰老增加。
- TTFields显著降低MSC迁移能力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出结果为后续分析接受TTFields治疗的胶质母细胞瘤患者中MSC的作用提供基础,需进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mesenchymal stromal cells (MSCs) within the glioblastoma microenvironment have been shown to promote tumor progression. Tumor Treating Fields (TTFields) are alternating electric fields with low intensity and intermediate frequency that exhibit anti-tumorigenic effects. While the effects of TTFields on glioblastoma cells have been studied previously, nothing is known about the influence of TTFields on MSCs. METHODS: Single-cell RNA sequencing and immunofluorescence staining were employed to identify glioblastoma-associated MSCs in patient samples. Proliferation and clonogenic survival of human bone marrow-derived MSCs were assessed after TTFields in vitro. MSC' characteristic surface marker expression was determined using flow cytometry, while multi-lineage differentiation potential was examined with immunohistochemistry. Apoptosis was quantified based on caspase-3 and annexin-V/7-AAD levels in flow cytometry, and senescence was assessed with ß-galactosidase staining. MSCs' migratory potential was evaluated with Boyden chamber assays. RESULTS: Single-cell RNA sequencing and immunofluorescence showed the presence of glioblastoma-associated MSCs in patient samples. TTFields significantly reduced proliferation and clonogenic survival of human bone marrow-derived MSCs by up to 60% and 90%, respectively. While the characteristic surface marker expression and differentiation capacity were intact after TTFields, treatment resulted in increased apoptosis and senescence. Furthermore, TTFields significantly reduced MSCs' migratory capacity. CONCLUSION: We could demonstrate the presence of tumor-associated MSCs in glioblastoma patients, providing a rationale to study the impact of TTFields on MSCs. TTFields considerably increase apoptosis and senescence in MSCs, resulting in impaired survival and migration. The results provide a basis for further analyses on the role of MSCs in glioblastoma patients receiving TTFields.
引用
- Strack M, Kückelhaus J, Diebold M, et al. Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells. J Neurooncol. 2024. PMID: 38900237. doi:10.1007/s11060-024-04740-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。